Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients:A retrospective study

被引:0
|
作者
Min Yuan [1 ]
Tian-You Chen [1 ]
Xiao-Rong Chen [2 ]
Yun-Fei Lu [2 ]
Jia Shi [2 ]
Wen-Si Zhang [2 ]
Chen Ye [2 ]
Bo-Zong Tang [2 ,3 ]
Zong-Guo Yang [2 ]
机构
[1] Department of Interventional Medicine, Shanghai Public Health Clinical Center, Fudan University
[2] Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University
[3] Department of Internal Medicine of Traditional Chinese Medicine, Shanghai East Hospital, Tongji University School of Medicine
关键词
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND Post-transarterial chemoembolization(TACE) liver failure occurs frequently in hepatocellular carcinoma(HCC) patients. The identification of predictors for postTACE liver failure is of great importance for clinical decision-making in this population.AIM To investigate the occurrence rate and predictive factors of post-TACE liver failure in this retrospective study to provide clues for decision-making regarding TACE procedures in HCC patients.METHODS The clinical records of HCC patients treated with TACE therapy were reviewed. Baseline clinical characteristics and laboratory parameters of these patients were extracted. Logistic models were used to identify candidates to predict post-TACE liver failure.RESULTS A total of 199 HCC patients were enrolled in this study, and 70 patients(35.2%) developed post-TACE liver failure. Univariate and multivariate logistic models indicated that microspheres plus gelatin embolization and main tumor size > 5 cm were risk predictors for postTACE liver failure [odds ratio(OR): 4.4, 95% confidence interval(CI): 1.2-16.3, P = 0.027; OR: 2.3, 95%CI: 1.05-5.3, P = 0.039, respectively]. Conversely, HCC patients who underwent tumor resection surgery before the TACE procedure had a lower risk for post-TACE liver failure(OR: 0.4, 95%CI: 0.2-0.95, P = 0.039).CONCLUSION Microspheres plus gelatin embolization and main tumor size might be risk factors for post-TACE liver failure in HCC patients, while prior tumor resection could be a favorable factor reducing the risk of post-TACE liver failure.
引用
收藏
页码:8535 / 8546
页数:12
相关论文
共 50 条
  • [41] Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma
    Atanas Pachev
    Lucas Raynaud
    Luisa Paulatto
    Marco Dioguardi Burgio
    Vincent Roche
    Carmela Garcia Alba
    Annie Sibert
    Matthieu Lagadec
    Juliette Kavafyan-Lasserre
    Catherine Paugam-Burtz
    Valérie Vilgrain
    Maxime Ronot
    European Radiology, 2021, 31 : 3267 - 3275
  • [42] Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
    Park, Kil Hyo
    Kwon, Soon Ha
    Lee, Yong Sub
    Jeong, Soung Won
    Jang, Jae Young
    Lee, Sae Hwan
    Kim, Sang Gyune
    Cha, Sang-Woo
    Kim, Young Seok
    Cho, Young Deok
    Kim, Hong Soo
    Kim, Boo Sung
    Kim, Yong Jae
    CLINICAL AND MOLECULAR HEPATOLOGY, 2015, 21 (02) : 158 - 164
  • [43] Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience
    Kedarisetty, Chandan K.
    Bal, Sipra
    Parida, Subhashree
    Jain, Mayank
    Bhadoria, Ajeet S.
    Varghese, Joy
    Venkataraman, Jayanthi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 11 (03) : 299 - 304
  • [44] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
    Zhang, Jin-Xing
    Chen, Yu-Xing
    Zhou, Chun-Gao
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Zu, Qing-Quan
    HEPATOLOGY RESEARCH, 2022, 52 (09) : 794 - 803
  • [45] Factors Associated with Transarterial Chemoembolization Outcome for Hepatocellular Carcinoma
    Thuy Tran Ngoc
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 51 - 51
  • [46] Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study
    Rebecca A. Miksad
    Sadahisa Ogasawara
    Fang Xia
    Marc Fellous
    Fabio Piscaglia
    BMC Cancer, 19
  • [47] Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study
    Miksad, Rebecca A.
    Ogasawara, Sadahisa
    Xia, Fang
    Fellous, Marc
    Piscaglia, Fabio
    BMC CANCER, 2019, 19 (01)
  • [48] The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients
    Weng, Fangbin
    Li, Xiaofei
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (01) : 783 - 784
  • [49] The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients
    Lin, Po-Ting
    Teng, Wei
    Jeng, Wen-Juei
    Hsieh, Yi-Chung
    Hung, Chen-Fu
    Huang, Chien-Hao
    Lui, Kar-Wai
    Chen, Yi-Cheng
    Lin, Chen-Chun
    Lin, Shi-Ming
    Sheen, I-Shyan
    Lin, Chun-Yen
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (02) : 635 - 643
  • [50] Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases
    Li, Shaohua
    Wang, Qiaoxuan
    Mei, Jie
    Wang, Jianwei
    Zhong, Xiao-Ping
    Ling, Yihong
    Guo, Zhixing
    Lu, Liang-He
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CANCER, 2019, 10 (20): : 5007 - 5014